PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Weight loss drug liraglutide is safe and effective in children under 12, study finds

Children aged 6 to under 12 saw BMI fall by 7.4%, in just over a year compared with placebo

2024-09-10
(Press-News.org) The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

Childen aged six to <12 years who took liraglutide for just over a year experienced a reduction in BMI of 7.4% compared to placebo and experienced improvements in blood pressure and blood sugar control.

The results of the SCALE Kids trial, the first study to examine the safety and efficacy of liraglutide in the paediatric population, offer hope that children who are living with obesity can lead healthier, more productive lives, say the researchers.

Lead author Professor Claudia Fox, of the Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, USA, says: “Obesity is the most common chronic disease of childhood. Left untreated, obesity in childhood almost universally persists into adulthood and is associated with significant ill health, including diabetes and cardiovascular disease, and for some, premature death.  Early intervention is therefore critical.  

“However, effective treatment options to date are limited.  The backbone of obesity treatment is lifestyle therapy – changes in diet and physical activity – but when used alone, the effect is modest and, as yet, no medication is approved for the treatment of general obesity in children who are younger than 12.

“Liraglutide is approved as an adjunct to lifestyle therapy in adults and adolescents with obesity and, in this study, we explored its safety and efficacy in under-12s.”

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.  It mimics action of a hormone called GLP-1 to reduce appetite and feelings of hunger, slow the release of food from the stomach and increase feelings of fullness after eating and is given daily, as an injection.

The phase 3 study, which was funded by liraglutide maker Novo Nordisk, involved 82 children (53.7% male) aged 6 to <12 years. At baseline, average age was 10 years, BMI was 31.0 kg/m2 and body weight was 70.2 kg (11st 1lb). 54.9% of children had ≥1 obesity-related complication, such as insulin resistance or early puberty.

56 children received daily injections of liraglutide (3mg or maximum tolerated dose) and 26 received weekly injections of placebo for 56 weeks. All of the participants received individualised counselling at every visit to encourage adherence to a healthy diet and regular physical activity (with the aim of doing 60 minutes a day of moderate to high intensity exercise).

At the end of the treatment period, the mean change in BMI was −5.8% for liraglutide and +1.6% for placebo – a difference of 7.4%.

Mean change in body weight was +1.6% for liraglutide and +10% for placebo – a difference of 8.4%.

A reduction in BMI of at least 5% was observed in 46.2% of children receiving liraglutide and 8.7% receiving placebo.

Children of this age are constantly growing and so body weight would be expected to increase over the course of a year. BMI takes into account height, as well as weight, and so is more informative, say the researchers.

Professor Fox says: “Although there is no consensus on the definition of a clinically meaningful BMI reduction in children, a 5% reduction has previously been shown to be associated with improvement in some obesity-related health conditions. 

“In our study, diastolic blood pressure and haemoglobin A1c [HbA1c], a measure of blood sugar control, improved more in children receiving liraglutide than in those receiving the placebo.”

Side-effects were common in both groups (89.3% of liraglutide recipients and 88.5% of placebo recipients). Gastrointestinal side effects (eg nausea, vomiting, diarrhoea) were the most common and occurred in 80.4% of children receiving liraglutide and 53.8% receiving placebo.

12.5% of the liraglutide recipients and 7.7% of the placebo recipients experienced serious side-effects.  Four of the 7 serious adverse events in the liraglutide group were gastrointestinal in nature and 10.7% of those in the liraglutide group discontinued treatment due to side-effects, versus none in the placebo group.

This is in line with what has previously been observed in adolescents and adults taking liraglutide.

BMI and body weight increased in both groups after treatment stopped.

The researchers conclude that liraglutide 3.0mg led to a greater reduction in BMI than placebo in children aged six to younger than 12 years living with obesity.  Liraglutide was well-tolerated and there were no new safety concerns.

Professor Fox adds: “The results of this study offer considerable promise to children living with obesity.

“To date, children have had virtually no options for treating obesity. They have been told to ‘try harder’ with diet and exercise. 

“Now with the possibility of a medication that addresses the underlying physiology of obesity, there is hope that children living with obesity can live healthier, more productive lives.”

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
2024-09-10
Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus. The European Society of Medical Oncology is highlighting the trial at its ESMO Congress 2024 in Barcelona, Spain. Surgery is required for these patients but at a high physical cost. Patients enrolled in this trial had signs that surgery would result in loss of the eye, the base of the skull bone, or both. However, in the randomized prospective trial EA3163, patients receiving chemotherapy ...

The glug of it all

2024-09-10
As Rohit Velankar, now a senior at Fox Chapel Area High School, poured juice into a glass, he could feel that the rhythmic glug, glug, glug was flexing the walls of the carton. Rohit pondered the sound, and wondered if a container’s elasticity influenced the way its fluid drained. He initially sought the answer to his question for his science fair project, but it spiraled into something more when he teamed up with his father, Sachin Velankar, a professor of chemical and petroleum engineering at the University of Pittsburgh Swanson School of Engineering.  They set up an experiment ...

UTA to build netted drone facility in Fort Worth

UTA to build netted drone facility in Fort Worth
2024-09-10
The University of Texas at Arlington is expanding its research and innovation capabilities by building a $2.3 million, state-of-the-art outdoor netted drone facility. The Maverick Autonomous Vehicle Research Center (MAVRC) will be located at the UT Arlington Research Institute (UTARI) in Fort Worth, with a planned completion date of January 2025. “MAVRC will significantly and positively impact UTA’s presence in the region by supporting the university-industry-government-community ecosystem focused ...

Streamlining energy regulations on Native American reservations could help alleviate poverty

2024-09-10
MADISON–Land was once set aside as Native American reservations because it was undesirable and low in resources, but now interested Native Americans may have economic leverage in the growing industry of clean energy. A team of researchers led by UW–Madison professors Dominic Parker and Sarah Johnston quantified the economic potential of wind and solar energy projects on these lands and discussed the regulatory barriers for tribes wishing to tap into it. “This is the first comprehensive ...

UT microbiologist Wilhelm honored as Fellow of the Royal Society of Canada

UT microbiologist Wilhelm honored as Fellow of the Royal Society of Canada
2024-09-10
Steven Wilhelm joins a distinguished roster this year with his election as a fellow of the Royal Society of Canada (RSC) Academy of Science. This recognition is the RSC’s highest honor in areas of arts, social sciences, humanities, and science. “The RSC inducts fellows to help them build a better future in Canada and the world. As a native Canadian, this honor is the pinnacle of what I could have hoped for in my career,” said Wilhelm, the Kenneth and Blaire Mossman Professor in UT’s Department of Microbiology. “It also provides an opportunity for me to work with my collaborators ...

NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody

NCCN Policy Summit explores how to build an inclusive cancer center workplace culture that better serves everybody
2024-09-10
WASHINGTON, D.C. [September 10, 2024] — The National Comprehensive Cancer Network® (NCCN®) held an oncology policy summit today in Washington, D.C., focused on Advancing Diversity, Equity, and Inclusion in the Cancer Workforce. The event featured a keynote address from Tiffany Wallace, PhD, Branch Director, Disparities Research Branch, National Cancer Institute (NCI) Center for Cancer Health Equity. Panel discussions focused on how to establish and prioritize a culture of diversity, equity, inclusion, and belonging and maintain the commitment through a changing policy landscape. A series of ...

Games, puzzles and reading can slow cognitive decline in the elderly — even in those with mild cognitive impairment

2024-09-10
By Ann Kellett, Texas A&M University School of Public Health The aging process can lead to diminished cognitive functioning for older adults. In addition, about 10 percent of people previously diagnosed with mild cognitive impairment develop Alzheimer’s disease or other forms of dementia every year. Although a few studies have found that activities such as putting together jigsaw puzzles can protect against cognitive aging, the benefits of these activities in preventing or postponing cognitive ...

An antidiabetic helps the immune system recognize reservoirs of HIV

An antidiabetic helps the immune system recognize reservoirs of HIV
2024-09-10
Researchers at Université de Montréal’s affiliated hospital research centre, the CRCHUM, say the discovery could help lessen and even eliminate viral loads in people undergoing antiretroviral therapy. Metformin, a drug used to treat type 2 diabetes, could help deplete the viral reservoir and eliminate it entirely in people living with HIV who receive antiretroviral therapy, Canadian researchers say in a new study. In 2021, a team led by immunologist Petronela Ancuta of Université de Montréal’s affiliated hospital research centre, ...

Department of Energy grant advances clean energy studies

Department of Energy grant advances clean energy studies
2024-09-10
Dr. Berna Hascakir, professor in the Harold Vance Department of Petroleum Engineering at Texas A&M University, was selected as part of a $17 million grant from the U.S. Department of Energy’s (DOE) Office of Fossil Energy and Carbon Management. The investment will support university-led projects that advance decarbonization and net-zero greenhouse gas emissions.    In partnership with Texas A&M, Texas Tech University, Howard University, and the University at Buffalo, this initiative unites three minority-serving ...

Finding the right path(way) to reduce fat accumulation in the liver

Finding the right path(way) to reduce fat accumulation in the liver
2024-09-10
Using a novel stem cell platform, a team of Medical University of South Carolina researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as metabolic dysfunction-associated steatotic liver disease, or MASLD. The MUSC team was led by Stephen Duncan, Ph.D., SmartState Endowed Chair in Regenerative Medicine at MUSC, and Caren Doueiry, an M.D., Ph.D. candidate in Duncan’s laboratory. The team reports its findings in the International Journal of Molecular Sciences. Almost a quarter of Americans have MASLD, formerly known as non-alcoholic fatty liver disease. It ...

LAST 30 PRESS RELEASES:

SwRI-developed instruments will study potential habitability of Jupiter’s moon Europa

Proposed scoring system may enhance equity in organ transplantation, increase transplant rates and improve patient survival

Survivors of childhood brain cancer are more likely to be held back in school

Updating offshore turbine designs to reflect storms’ complexity is key

Hospital strain during the COVID-19 pandemic and outcomes in older racial and ethnic minority adults

Scientists unveils key role of “selfish DNA” in early human development

Bonobos may be more vulnerable than previously thought, suggests genetics study

Scripps Research scientists discover chemical probes for previously “undruggable” cancer target

Giant Magellan telescope begins primary mirror support system testing

Experimental cancer drug eliminates bone metastases caused by breast cancer in lab models

Political candidates who fight climate change stand to benefit in election

Stand up to Cancer announces new grants supporting pioneering research in six cancer types

Researchers awarded $1.3M to help military Veterans battling Acute Myeloid Leukemia

New hub for high-energy astrophysics — CTAO Science Data Management Centre opens at DESY in Zeuthen

JMIR publications CEO and Executive Editor Gunther Eysenbach achieves #1 ranking as most cited researcher in Medical Informatics for fifth consecutive year

ERC grant for groundbreaking wearable health tech

NIH announces winners of prize competition to improve postpartum maternal health and health equity through innovative diagnostics

APS and SPR honor Dr. Cynthia F. Bearer with the 2025 Mary Ellen Avery Neonatal Research Award

Election delays and voter trust

US air pollution monitoring network has gaps in coverage, say researchers

Continuous monitoring of fatigue in factory workers

Farmer ants’ wearable bacteria

Political polarization and trust

Study uncovers how silkworm moth's odor detection may improve robotics

New study links obesity to elevated hypertension risk among young middle eastern women

How ‘vaccinating’ plants could reduce pesticide use and secure global food supplies

Seven new frog species discovered in Madagascar: sounds like something from Star Trek

New temperatures in two thirds of key tropical forest

Fearful memories of others seen in mouse brain

Rangers lead ground-breaking effort to monitor Uganda's lion population in critical stronghold

[Press-News.org] Weight loss drug liraglutide is safe and effective in children under 12, study finds
Children aged 6 to under 12 saw BMI fall by 7.4%, in just over a year compared with placebo